Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Conditions
Keywords
Copanlisib, Ibrutinib, Recurrent/ Refractory, PCNSL, Brain lymphoma, Primary Central Nervous System Lymphoma, BTK, PI3K
Brief summary
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
Interventions
DRUGIbrutinib
(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
DRUGCopanlisib
(MTD) Copanlisib 60 mg weekly (3w on/1w off)
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an open-label, phase Ib/II trial of the pan-Phosphoinositide 3-kinase (PI3K) inhibitor Copanlisib in combination with the Bruton Tyrosine Kinase (BTK) inhibitor Ibrutinib in patients with recurrent or refractory primary central nervous lymphoma (PCNSL and frail/elderly newly diagnosed PCNSL patients, not eligible to receive standard first-line chemotherapy).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients eligible for inclusion in this study must meet ALL the following criteria: * Men and woman who are at least 18 years of age on the day of consenting to the study. * Histologically documented PCNSL * Relapsed/refractory PCNSL or newly diagnosed PCNSL patients who are deemed medically ineligible by the treating investigator (phase II only) to receive standard first-line chemotherapy. All recurrent/refractory patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences. * For recurrent/refractory patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days of study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days of study registration (at the discretion of the investigator). * ECOG performance status ≤ 2. * Life expectancy of \> 3 months (in the opinion of the investigator). * Adequate bone marrow and organ function shown by: * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L * Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days prior to study registration * Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration * International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal * Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome * Serum creatinine ≤ 2 times the upper limit of normal * Creatinine clearance ≥ 30 mL/min * Lipase ≤ 1.5 x upper limit of normal * Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 30 days (for WOCBP) and 90 days (for men) after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. * The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence * The use of condoms by male patients is required unless the female partner is permanently sterile. Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry * Must be able to tolerate MRI/CT scans * Must be able to tolerate lumbar puncture and/or Ommaya taps * Must have recovered to grade 1 toxicity from prior therapy * Able to submit up to 20 unstained formalin-fixed, paraffin-embedded (FFPE) slides from the initial or most recent tissue diagnosis for correlative studies NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.
Exclusion criteria
Patients eligible for this study must NOT MEET ANY of the following criteria: * Active concurrent malignancy requiring active therapy * Newly diagnosed PCNSL who qualify for standard methotrexate-based chemotherapy Excluded medical conditions: * Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association \> Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification * Uncontrolled hypertension despite optimal medical management (per investigator"s assessment) * Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin \>8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of \>8% * Patient is known to have an uncontrolled active systemic infection (\>CTCAE grade 2) and recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug * Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment * Non-healing wound, ulcer or bone fracture * Not recovered to a grade 1 from the toxic effects of prior therapy if clinically relevant in the opinion of the investigator (e.g. alopecia) * Known bleeding diathesis (eg, von Willebrand"s disease) or hemophilia * Known history of infection with human immunodeficiency virus (HIV) or history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests, or any uncontrolled active systemic infection * Patient underwent major systemic surgery ≤ 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug * Unable to swallow capsules or disease significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction * Any life-threatening illness, medical condition including uncontrolled diabetes mellitus (DM), uncontrolled hypertension or organ system dysfunction that, in the opinion of the investigator, could compromise the subject"s safety or put the study outcomes at undue risk * Lactating or pregnant Excluded previous Therapies and medications: * Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 21 days of the first dose of study drug * Prior treatment with a PI3K inhibitor, AKT inhibitor, or mTOR inhibitor (prior ibrutinib exposure is allowed) * Any targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter * Use of radio- or toxin-immunoconjugates within 70 days of the first dose of study drug * Concurrent use of warfarin or other vitamin K antagonists (need to be stopped 7 days prior to starting on trial drug) * Concurrent use of a strong cytochrome P450 (CYP) 3A4/5 inhibitor and inducers (see Appendix 1) (need to be stopped 2 weeks prior to starting on trial drug) * Enzyme-inducing antiepileptic drugs (EIAED) need to be discontinued and switched to a nonnon-EIAED 2 weeks prior to starting on trial drug) * Patient requires more than 4 mg of dexamethasone daily or the equivalent * Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of \> 5 mg/day or prednisone or the equivalent. Participants must be off of immunosuppressant therapy for at least 28 days prior to the first dose of the study drug * Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of \> 5 mg/day of prednisone) within 28 days of the first dose of study drug * Prior allogeneic stem cell transplant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose (MTD) (phase Ib) | 1 year | The "3+3" design will be applied in the phase Ib portion of the trial. |
| overall response rate (ORR) (phase II) | 1 year | To explore the therapeutic efficacy measured by overall response rate (ORR) of Copanlisib in combination with Ibrutinib in patients with refractory/relapsed PCNSL or newly diagnosed PCNSL not able to tolerate standard chemotherapy (phase II)This study will use the modified International Primary CNS Lymphoma Collaborative Group (IPCG)12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse events in terms of incidence and severity (phase Ib and II) | 2 years | adverse events at each visit with the NCI CTCAE v4.03 used as a guide for the grading of severity. |
| progression free survival (PFS) (phase II) | 2 years | Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause. |
| duration of response (DOR) (phase II) | 2 years | Duration of response is defined as the time from the date of first occurrence of CR or PR to the date of the first documented PD or death due to any cause. |
| overall survival (OS) (phase II) | 2 years | Overall survival time (OS) is defined as the time from treatment start to the date of death due to any cause. |
| To evaluate cerebral spinal fluid (CSF) pharmacokinetics of Copanlisib and Ibrutinib and correlate with plasma pharmacokinetics (phase Ib) | 2 years | — |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORChristian Grommes, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed